Wells Fargo Maintains Overweight on Ironwood Pharmaceuticals, Lowers Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Mohit Bansal maintains an Overweight rating on Ironwood Pharmaceuticals (NASDAQ:IRWD) but lowers the price target from $14 to $12.
August 09, 2024 | 10:30 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Wells Fargo analyst Mohit Bansal maintains an Overweight rating on Ironwood Pharmaceuticals but lowers the price target from $14 to $12.
The Overweight rating suggests a positive outlook, but the lowered price target indicates some concerns about future performance. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100